Affiliations: [a] Université de Lorraine, ENSAIA, UR AFPA, EA 3998, USC INRA 0340, Nancy, France
| [b] Université de Lyon 1, Lyon Neuroscience Research Center; CNRS UMR5292; INSERM U1028; Lyon, France
| [c] Laboratoire de Biochimie, Hôpital Central, CHU de Nancy, CO n°34, Nancy, France
Correspondence:
[*]
Correspondence to: Dr Catherine Malaplate-Armand, Université de Lorraine, ENSAIA, UR AFPA (USC INRA 0340),2 avenue de la forêt de Haye, Vandœuvre-lès-Nancy, F-54500, France. Tel.: +33 383 595 765; Fax: +33 383 596 181; E-mail: [email protected].
Note: [1] Co-senior authors.
Abstract: Oligomeric amyloid-β (Aβ) peptide contributes to impaired synaptic connections and neurodegenerative processes, and as such, represents a primary therapeutic target for Alzheimer’s disease (AD)-modifying approaches. However, the lack of efficacy of drugs that inhibit production of Aβ demonstrates the need for a better characterization of its toxic effects, both on synaptic and neuronal function. Here, we used conditioned medium obtained from recombinant HEK-AβPP cells expressing the human amyloid-β protein precursor (Aβ-CM), to investigate Aβ-induced neurotoxic and synaptotoxic effects. Characterization of Aβ-CM revealed that it contained picomolar amounts of cell-secreted Aβ in its soluble form. Incubation of primary cortical neurons with Aβ-CM led to significant decreases in synaptic protein levels as compared to controls. This effect was no longer observed in neurons incubated with conditioned medium obtained from HEK-AβPP cells grown in presence of the γ-secretase inhibitor, Semagacestat or LY450139 (LY-CM). However, neurotoxic and pro-apoptotic effects of Aβ-CM were only partially prevented using LY-CM, which could be explained by other deleterious compounds related to chronic oxidative stress that were released by HEK-AβPP cells. Indeed, full neuroprotection was observed in cells exposed to LY-CM by additional treatment with the antioxidant resveratrol, or with the pluripotent n-3 polyunsaturated fatty acid docosahexaenoic acid. Inhibition of Aβ production appeared necessary but insufficient to prevent neurodegenerative effects associated with AD due to other neurotoxic compounds that could exert additional deleterious effects on neuronal function and survival. Therefore, association of various types of protective agents needs to be considered when developing strategies for AD treatment.
